INmune Bio Inc. Patent Claims Covering INB16 Cell Line And INKmune Therapeutic Composition given Favorable Patentability Opinion By International Search Authority
Portfolio Pulse from Benzinga Newsdesk
INmune Bio, Inc. (NASDAQ:INMB) has received a favorable patentability opinion from the International Search Authority for its proprietary cell line, INB16, and the INKmune™ therapeutic composition. The company is exploring several potential commercial applications of the INB16 cell line, including uses in cancer research and therapeutic uses. INmune Bio intends to leverage the favorable written opinion to accelerate patent issuance for its inventions. The company has also opened an IND for a US trial of INKmune™ in metastatic castration-resistant prostate cancer.
October 31, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
INmune Bio's favorable patentability opinion for its INB16 cell line and INKmune therapeutic composition could potentially lead to commercial applications and patent issuance. The company's upcoming US trial of INKmune in metastatic castration-resistant prostate cancer could also have significant implications.
The favorable patentability opinion for INmune Bio's INB16 cell line and INKmune therapeutic composition could potentially lead to commercial applications and patent issuance, which could increase the company's market value. Additionally, the upcoming US trial of INKmune in metastatic castration-resistant prostate cancer could potentially lead to a new treatment option, which could also increase the company's market value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100